Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The once daily tablets reduced the risk of death by 60% compared to chemotherapy.
read more
The expansion creates commercial-scale batch tablet capacity by bringing spray drying and tableting to the same site.
read more
Available in tablets for oral use and oral suspension, Tivicay PD is the first of its kind available to pediatric patients.
read more
Bixlenvo is a once-daily single tablet HIV treatment for virologically-suppressed adults.
read more
AstraZeneca plans to launch Zegfrovy in the U.S. during the fourth quarter of 2026.
read more
The BTK inhibitor met its primary and key secondary endpoints, while also demonstrating a favorable safety profile.
read more
Etcamah in combination with a CDK4/6 inhibitor reduced the risk of disease progression or death by 56% versus standard-of-care treatment.
read more
The first prophylactic for all three types of HAE, the drug reduced attack rates by 83%.
read more
Etcamah didn't meet the primary endpoint of progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer.
read more
The rebrand comes as Novo Nordisk races to close the gap with obesity-drug rival Eli Lilly.
read more
This is the company’s third positive phase 3 readout for its DT120 orally disintegrating tablet.
read more
The CPHI Pharma Awards has categories for drug development, digital transformation, supply chain, manufacturing, sustainability, partnerships, and leadership.
read more
Linistinib is the only small molecule in late-stage development for active thyroid eye disease.
read more
The oral drug is expected to reduce the risk of eGFR decline and end-stage kidney disease.
read more
This marks the second FDA approval for Inluriyo in less than a year, following its September 2025 approval as a monotherapy.
read more